• Publications
  • Influence
FGF23 induces left ventricular hypertrophy.
Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascularExpand
  • 1,332
  • 99
  • PDF
A controlled trial of renal denervation for resistant hypertension.
BACKGROUND Prior unblinded studies have suggested that catheter-based renal-artery denervation reduces blood pressure in patients with resistant hypertension. METHODS We designed a prospective,Expand
  • 1,544
  • 68
  • PDF
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately. Patients want toExpand
  • 5,714
  • 63
  • PDF
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Fibroblast growth factor 23 (FGF23) regulates phosphorus metabolism and is a strong predictor of mortality in dialysis patients. FGF23 is thought to be an early biomarker of disordered phosphorusExpand
  • 814
  • 54
  • PDF
Clinical Practice Guidelines for the Management of Hypertension in the Community
Michael A. Weber, MD; Ernesto L. Schiffrin, MD; William B. White, MD; Samuel Mann, MD; Lars H. Lindholm, MD; John G. Kenerson, MD; John M. Flack, MD; Barry L. Carter, Pharm D; Barry J. Materson, MD;Expand
  • 637
  • 34
  • PDF
Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women.
Previous studies indicate that leptin secretion is regulated by insulin-mediated glucose metabolism. Because fructose, unlike glucose, does not stimulate insulin secretion, we hypothesized that mealsExpand
  • 650
  • 32
  • PDF
Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association.
Much has been published in the past 20 years on the use of measurements of arterial stiffness in animal and human research studies. This summary statement was commissioned by the American HeartExpand
  • 601
  • 31
  • PDF
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
AIMS The SYMPLICITY HTN-3 randomized, blinded, sham-controlled trial confirmed the safety of renal denervation (RDN), but did not meet its primary efficacy endpoint. Prior RDN studies haveExpand
  • 381
  • 26
  • PDF
DNMT3A mutations in acute myeloid leukemia.
BACKGROUND The genetic alterations responsible for an adverse outcome in most patients with acute myeloid leukemia (AML) are unknown. METHODS Using massively parallel DNA sequencing, we identifiedExpand
  • 618
  • 19
  • PDF
The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for
While risk scores are invaluable tools for adapted preventive strategies, a significant gap exists between predicted and actual event rates. Additional tools to further stratify the risk of patientsExpand
  • 422
  • 17
  • PDF